GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Albert Frendo joins Lidion Bank Board of Directors
He brings with him more than three decades of banking experience.
Why do 9 out of 10 AI projects fail? Brixon AI CEO points to three common mistakes
Christoph Sauerborn shares insights from his experience working with AI in industry.
Wayne Formosa joins Herd Gaming as CFO
Wayne has over 10 years of experience in the iGaming sector.
‘The best of GO is still ahead of us’: CEO Nikhil Patil as GO crosses €254 million revenue milestone
The company has just announced 'a milestone year on every front.'
